

News Releases

All Years



Search

GO

[Advanced Search](#)

May 18, 2020

Portola Pharmaceuticals Announces Virtual 2020 Annual Stockholder Meeting

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that, due to the public health impact of the coronavirus (COVID-19) pandemic and to prioritize the health and well-being of...

May 14, 2020

U.S. Centers for Medicare & Medicaid Services (CMS) Proposes Extending New Technology Add-on Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa® for Third Year

- Reinforcing Breakthrough Innovation and Clinical Value of Andexxa, Proposed Extension Will Support Patient Access by Continuing to Provide Medicare Reimbursement in the Hospital Setting -

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has proposed extending the New Technology Add-on Payment (NTAP) for Andexxa®...

May 11, 2020

Portola Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update

- Reached Agreement to be Acquired by Alexion; Transaction Expected to Close in Third Quarter -

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended March 31, 2020, and provided a corporate update, including the Company's actions to...

May 5, 2020

Portola Pharmaceuticals Cancels First Quarter 2020 Financial Results Webcast and Conference Call Following Agreement to be Acquired by Alexion

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) (the "Company" or "Portola") today announced that it is cancelling its webcast and conference call to discuss the Company's financial results for the...

May 5, 2020

Alexion to Acquire Portola

- Expands and diversifies Alexion's hematology, neurology and critical care commercial portfolio with transformative Factor Xa inhibitor reversal agent -

BOSTON & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) announced today that they have entered into a...

May 1, 2020

Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) announced today that on April 30, 2020, the Compensation Committee of the Board of Directors approved, effective as of April 30, 2020, the grant to...

Apr 23, 2020

Portola Pharmaceuticals to Announce First Quarter 2020 Financial Results on Monday, May 11, 2020

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended March 31, 2020, and...

Apr 7, 2020

Portola Pharmaceuticals Announces the Establishment of a Permanent J-code for Andexxa by the Centers for Medicare & Medicaid Services, Effective July 1, 2020

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that the Centers for Medicare & Medicaid Services (CMS) established a new permanent J-code for Andexxa® [coagulation factor Xa...

Apr 1, 2020

Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) announced today that on March 31, 2020, the Compensation Committee of the Board of Directors approved, effective as of March 31, 2020, the grant to...

Mar 18, 2020

Portola Pharmaceuticals Announces Proactive Steps Supporting Public Health Efforts to Combat Coronavirus (COVID-19)

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced proactive steps the Company is taking in support of public health efforts to prevent furtherspread of coronavirus (or COVID-19) around...

Show 10  per page

 [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) ... [27](#) 



<https://investors.portola.com/news-releases?ID=2376001&c=198136&p=irol-newsArticle&l=10>